At least 19 biotechs and pharmas are slated to report earnings this week. Pfizer Inc. (NYSE:PFE), which starts off the week, will be closely watched for details on its pursuit to acquire fellow big pharma AstraZeneca plc (LSE:AZN; NYSE:AZN). Last week, AZ rejected a sweetened offer by Pfizer (see "Pulling Off the AZ Gambit," A12). Pfizer is expected to report quarterly EPS growth of 8% despite an 11% decline in revenues to $12.1 billion.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Salix Pharmaceuticals Inc. (NASDAQ:SLXP) are both anticipated to announce an increase in quarterly EPS of more than 40%. Ligand, which receives royalties